N/A
Completed N=101
A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema
Source: ClinicalTrials.gov NCT01805323 ↗Enrolled (actual)
101
Serious AEs
4.0%
Results posted
May 2014
Primary outcomePrimary: Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) — 6.3; 1.4 Lines
Summary
This retrospective chart review study will describe the history of patients with retinal disease with macular edema to whom OZURDEX® (dexamethasone intravitreal implant) is administered, and assess treatment patterns and visual outcomes. OZURDEX® was previously administered according to general clinical practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Peak Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) |
6.3; 1.4 | — |
| SECONDARY Peak Mean Change From Baseline in Central Retinal Thickness (CRT) |
474.4; -183.4 | — |
Eligibility Criteria
Inclusion Criteria
- Retinal disease involving macular edema
- Received at least one OZURDEX® injection
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01805323). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.